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ABSTRACT: In this work, two different approaches have been developed to predict the food effect and the bioequivalence of
marketed itraconazole (ITRA) formulations. Kinetic solubility and simultaneous dissolution−permeation tests of three (ITRA)
formulations (Sporanox capsules and solution and SUBA-ITRA capsules) were carried out in simulated fasted and fed states.
Fraction of dose absorbed ratios estimating food effect and bioequivalence were calculated based on these results and were
compared to the in vivo study results published by Medicines Agencies. The comparison demonstrated that kinetic solubility
and flux values could be used as input parameters for biopharmaceutics modeling and simulations to estimate food effect and
bioequivalence. Both prediction methods were able to determine a slightly negative food effect in the case of the Sporanox
solution and also a pronounced positive food effect for the Sporanox capsule. Superior bioavailability was predicted when the
Sporanox solution was compared to the Sporanox capsule (in agreement with in vivo data).
KEYWORDS: BioFLUX, dissolution−permeation, membrane transport, absorption, itraconazole, supersaturation, kinetic solubility,
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1. INTRODUCTION
Improving the in vivo predictive power of dissolution tests for
biopharmaceutics classification system (BCS) class II type
drugs has become one of the major challenges of the
pharmaceutical industry.1,2 Among the underlying reasons for
the poor in vivo predictive power is the use of solubilizing
agents, such as surfactants, bile salts, cyclodextrins (CD) or
even polymers, that may influence not only the dissolution and
the solubility but also the membrane transport of such
solubility limited active pharmaceutical ingredients (API).3−8
Solubility limited cases can further be categorized based on the
limiting step of transport: unstirred water layer (UWL) or
epithelial membrane permeation.3,9,10 In cases of lipophilic
compounds where cellular membrane permeation is very fast,
UWL permeation is often the rate-limiting step of
absorption.11−15 While the bile micelles and CDs usually
increase the solubility of lipophilic compounds it has been
realized that they decrease the effective permeability (Peff) due
to a reduction of the fraction of free drug at the epithelial
membrane surface and/or the reduction of the diffusion
coefficient in the UWL caused by the enlarged hydrodynamic
radius of the micelle or CD complex as compared to the pure
API.16−26 Therefore, the balance of the solubility increase and
the Peff decrease determines the direction and the extent of the
food or CD effect.17
Part of the gastrointestinal unified theoretical (GUT)
framework mathematical model, assuming that both free
drug and micelle bound drug permeate through the UWL by
self-diffusion was found to be appropriate for the prediction of
the fraction of dose absorbed (Fa) in the cases of lipophilic
drugs with UWL limited absorption, by Sugano et al.10,27
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There have been many attempts to characterize formulations
with novel in vitro tests and apparatuses better. For poorly
water-soluble compounds, the determination of kinetic
solubility, i.e., the maximum concentration in a supersaturated
solution that can be obtained at the moment of precipitation,28
is of high importance. When an excess amount of API is added
to such a solution and a new amorphous phase is forming, this
solubility value is called amorphous instead of kinetic.29 The
supersaturation ratio4,30 (the ratio of the dissolved amount of
the drug relative to its equilibrium crystalline solubility
measured in the same media) may be valuable information
in terms of characterizing the API. Solubility tests have also
been applied to assess the effect of formulation excipients on
the extent and duration of supersaturation.31,32 Although it has
been suggested that kinetic or amorphous solubility data may
be useful to estimate bioavailability enhancement caused by
the amorphization of the API,29,33,34 this data has only been
used sparsely as an input parameter for prediction of Fa and
food effect,35 and has never been used to estimate the
bioequivalence of generic drug products.
In recent years, many new in vitro tools have been developed
to improve the in vitro in vivo correlation (IVIVC) by the
simultaneous testing of dissolution and absorption.36,37 The
parallel artificial membrane permeability assay (PAMPA) has
been shown to be predictive of passive transcellular
permeability,38 while having the advantage of being a
reproducible and cost-effective way of testing formulations
compared to cell-based assays or animal tests. Therefore, it was
proposed that a scaled-up version of a PAMPA-like setup could
become a way of combining dissolution and absorption testing.
A small volume (16−20 mL) side-by-side diffusion cell
apparatus called μFLUX, and a large volume (850−1000
mL) version MacroFLUX, was recently developed and proven
to be a valuable tool in formulation development.4,30,39−42 The
BioFLUX apparatus was a novel device that incorporates an
absorption compartment into a USP II dissolution apparatus,
like MacroFLUX, while changing the working volume in the
dissolution vessel from 900 mL to a more biorelevant 250
mL.9,43,44 Flux data generated with this setup has not yet been
published. Although by enabling simultaneous measurement of
dissolution and absorption rates, it has the potential to
improve IVIVC.41,39 Flux values have yet been sparsely used as
an input parameter in a predictive model for the calculation of
food effect and bioequivalence from an oral dosage form.
Itraconazole (ITRA), a BCS II class antifungal drug, was
chosen as a model compound. ITRA is a very lipophilic weak
base (pKa = 3.87)
41 with extremely low aqueous solubility and
pH-dependent permeability.45 The first commercial solid
formulation of ITRA, Sporanox capsules, (Janssen Pharma-
ceutica, Beerse, Belgium) contain the API in amorphous form
dispersed with hydroxypropylmethylcellulose (HPMC) on
sugar spheres.46 This formulation uses the advantage of the
high surface area of small spray-dried particles dispersed on the
sugar spheres, and also the amorphous state to improve drug
dissolution. The capsule formulation is supposed to be taken
after a full meal,47 which limits its utility as patients being
unable to take solid food are excluded. In contrast, Sporanox
oral solution, marketed 5 years after the capsule, has shown
higher bioavailability in the fasted state than in the fed state,
and therefore may be advantageous in therapy for such
patients.48
The oral solution contains 10 mg/mL ITRA in a pH 2
media. In order to reach around a four magnitude higher
concentration in solution than the thermodynamic solubility of
the crystalline drug at that pH, the formulation contains 400
mg/mL of (2-hydroxypropyl)-β-cyclodextrin (HP-β-CD).47,48
The oral bioavailability of ITRA when administered as oral
solution and capsule dosage forms was 35% and 10% in rats,
respectively.49,50 The absolute oral bioavailability of Sporanox
solution in the fed state when administered to humans was
found to be 55%.47,48 Human data also showed a significant
difference between the bioavailability of the solution and
capsule forms; therefore, the solution and capsule dosage forms
are not bioequivalent and cannot be used interchangeably.47,48
SUBA-Itraconazole (SUBA-ITRA) is a novel amorphous
solid dispersion (ASD) containing ITRA in a pH-dependent
polymeric matrix (hydroxypropylmethylcellulose-phthalate,
HPMC-P) to enhance its dissolution and intestinal absorption.
Although with a halved dose compared to the innovator
product (Sporanox capsules), it has failed to meet
bioequivalence criteria but showed therapeutic equivalence.51
Currently, it is available in Australia and Germany under the
trade name Lozanoc (Mayne Pharma Ltd.), and in Spain as
Itragerm.
The aim of this study was to predict food effect and
bioequivalence for three marketed formulations of ITRA
(Sporanox capsules, Sporanox solution, SUBA-ITRA capsules)
by using the results of state of the art experimental techniques,
like kinetic solubility and simultaneous dissolution−absorption
measurements, as input parameters for biopharmaceutics
modeling and simulations, and then to compare the perform-
ance of the different approaches.
2. EXPERIMENTAL SECTION
2.1. Materials. Crystalline itraconazole (ITRA) (706 g/
mol, structure shown in Figure 1) and buffer components
(NaH2PO4, NaOH, NaCl, KCl, HCl) were purchased from
Sigma-Aldrich Co. LLC. (St. Louis, MO, USA). (2-
Hydroxypropyl)-β-cyclodextrin (HP-β-CD), with the molar
substitution degree = 0.64, was purchased from Roquette
Freŕes (Lestrem, France). Hydroxypropyl methylcellulose
(HPMC 2910) was obtained from Aqualon, Hercules
(Zwijndrecht, The Netherlands), and hydroxypropyl methyl-
cellulose-phthalate (HPMC-P) was purchased from Shin-Etsu
Pharma & Food Materials Distribution GmbH (Wiesbaden,
Germany). The astrointestinal tract (GIT) lipid and acceptor
sink buffer (ASB) were obtained from Pion Inc. (Billerica, MA,
USA). Simulated intestinal fluid (SIF) powder was purchased
from Biorelevant.com (London, U.K.). Itraconazole marketed
formulations were purchased from the listed companies:
Sporanox solution and capsules from Johnson & Johnson
(Beerse, Belgium), SUBA-Itraconazole capsules from Mayne
Figure 1. Structure of itraconazole.
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Pharma (Salisbury, Australia). Table 1 summarizes the
composition of the ITRA containing marketed formulations.
2.2. Methods. 2.2.1. Solubility Assays. 2.2.1.1. Thermody-
namic Solubility Assay. The saturation shake flask (SSF)
method53,54 was used to determine the thermodynamic
solubility of ITRA in pH 1.2 simulated gastric fluid (SGF),
in pH 6.5 phosphate buffer (FaSSIF blank), pH 5 acetate
buffer (FeSSIF blank) and pH 7.4 ASB. The sample was added
in excess to the aqueous buffer solutions to produce a
suspension. At a controlled temperature of 37.0 ± 0.1 °C, the
solution containing solid excess of the sample was vigorously
stirred for a period of 6 h, followed by a further sedimentation
period of 18 h (stirrer turned off). Three aliquots were
carefully withdrawn from the liquid using a fine glass pipet and
were diluted with solvent as necessary. The concentration of
the saturated solution was measured by UV spectroscopy using
a JASCO V 550 UV/vis spectrophotometer. Three replicate
solubility measurements were carried out at each of the tested
conditions. The solid phase after the assay was not
characterized.
2.2.1.2. Kinetic Solubility Measurements. Note that, in the
context of this work, solubility measured by this method will be
called kinetic solubility because the form of the solid phase
precipitating during these assays was not characterized. A
concentrated (1 mg/mL) stock solution of ITRA was prepared
using 2 N HCl solution as a solvent. Ten mL of dissolution
medium was stirred at 200 rpm and held at 37 °C by
circulating water through a heating block mounted to a Pion
μDISS profiler (Pion Inc., Billerica, MA). The stock solution
was added in 5 μL aliquots to the equilibrated FaSSIF or
FeSSIF buffer containing predissolved additives (15.4 mg/mL
HP-β-CD or 300 μg/mL HPMC 2910 or 300 μg/mL HPMC-
P). To readjust the pH of the media after every addition of the
stock solution, 1 N NaOH was used. During and after addition
of the stock solution, UV probes connected to a Pion Rainbow
Dynamic Dissolution Monitor (Pion Inc., Billerica, MA)
system were used to detect changes in UV spectra thus
enabling the detection of precipitation, which provides
information about the kinetic solubility limit. Light scattering
was detected by monitoring the extinction at nonabsorbing
wavelengths (400 nm).
2.2.2. Flux Experiments. Marketed formulations of ITRA
were tested using BioFLUX (Pion Inc., Billerica, MA). In this
device, the acceptor compartment is integrated with a
permeable membrane, an overhead stirrer. and a fiber optic
UV probe (10 mm path length), which is then inserted into the
500 mL vessel of a USP II apparatus (Erweka DT 126
Dissolution Tester, Heusenstamm Germany) (Figure 2). A
scaled-up version of the PAMPA membrane, which previously
has shown good compatibility with formulation excipients like
HP-β-CD and biorelevant media, was chosen as the integrated
membrane.39,55 This artificial GIT-mimicking membrane was
formed by impregnating the filter support (hydrophobic
PVDF, polyvinylidenfluoride, 0.45 μm pore size, 3.69 cm2)
with 50 μL of GIT lipid solution (Pion Inc., Billerica, MA).
This membrane was separating the dissolution (donor)
compartment from the acceptor compartment containing 20
mL of pH 7.4 ASB (Pion Inc., Billerica, MA). In the case of the
fasted state, the experiment began in 200 mL of pH 1.6 buffer,
simulating gastric conditions (SGF) on the donor side. For the
initial 30 min of the experiment, the acceptor compartment
was not connected to the donor compartment. After 30 min
the media in the dissolution vessel was converted to fasted
state simulated intestinal fluid (FaSSIF V1) (pH 6.5) by
adding 50 mL of a specially formulated concentrate42
containing SIF powder (biorelevant.com); the acceptor
compartment was then added to begin the permeation
experiment. In the case of fed state assays, 250 mL of fed
state simulated intestinal fluid (FeSSIF V1) was used in the
donor compartment. No media change was carried out, and
the acceptor compartment was assembled into the dissolution
vessel from the beginning of the experiments. On the basis of
the USP recommendation for ITRA containing capsules, a
stirring speed of 100 rpm was selected for agitation of the
donor compartment.56 To study the efficiency of stirring in the
acceptor compartment, the flux data for a highly permeable
model compound, propranolol, was compared for 0, 250, 450,
and 600 rpm stirring speeds. There was a significant difference
between the flux results in the case of stirring and nonstirring,
though the results were found to be within the standard
deviation of each other for every stirring speed (250, 450, and
600 rpm). Thus, the rate of 450 rpm was selected for all assays.
The integrated fiber-optic (FO) UV probes were positioned in
the donor and acceptor compartments and connected to the
Rainbow Dynamic Dissolution Monitor instrument (Pion Inc.,






additive load of additive
Sporanox solution 100 mg/10 mL HP-β-CD 4000 mg/10
mL47,48
Sporanox capsules 100 HPMC 2910 not published
SUBA-ITRA
capsules
50 HPMC-P 75 mg/capsule52
Figure 2. Schematic (on the left) and image (on the right) of the dissolution−flux device used in this study (BioFLUX).
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Billerica, MA, USA), enabling real-time concentration
monitoring. The flux (J) across the membrane was calculated






where the flux of a drug through the membrane is defined as
the amount (m) of drug crossing a unit area (A) perpendicular
to its flow per unit time (t). Early fluxes were calculated from
the linear portion of the appearance profiles (50−120 min).
2.2.3. Estimation of Fraction Absorbed Ratios Based on
Sugano’s Method..9,10 The fraction absorbed (Fa) ratio for the
















where PUWL is the unstirred water layer permeability of the
drug, S is the solubility, and VGI is the effective fluid volume in
the gastrointestinal tract in fed or fasted conditions denoted by
corresponding subscripts.
The food effect prediction approach published by Sugano et
al.9 Equation 2 was adapted in this study to calculate Fa ratio











where parameters of the test and reference drug product can be
substituted accordingly.
Effective UWL permeability in a particular medium would
be proportional to the effective diffusivity of the API
containing complexes (DUWL,eff), and reversely proportional












mono UWL,mono mic UWL,mic
eff
(4)
where fmono and fmic are the fractions of the free monomer and
micelle bound API correspondingly ( fmono+ fmic = 1), while
DUWL,mono and DUWL,mic are the diffusion coefficients of the free
monomer and micelle bound drug in the UWL.
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where Smicelles is the solubility in biorelevant media containing
bile micelles and Sbuffer is the solubility in the corresponding
buffer without bile micelles.
When cyclodextrins are also present in the solution, eq 4












mono UWL,mono mic UWL,mic CD UWL,CD
eff
(6)
where f CD is the fraction of the cyclodextrin complex bound
molecule ( fmono + fmic + f CD = 1) and DUWL,CD is the diffusion
coefficients of CD complex bound drug in the UWL. Equation






S S fif , otherwise 1mono
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micelles CD
buffer micelles CD mono (7)
where Smicelles+CD is the solubility in biorelevant media
containing not only bile micelles and lecithin but also
cyclodextrin.
For the chosen parameters and assumptions, the diffusion
coefficient of the free monomer (Dmono) of ITRA and the
cyclodextrin complex (assuming ITRA-cyclodextrin ratio
1:3)57,58 was calculated using (eq 8).59 The diffusion
coefficient of the FaSSIF micelles was set as 3.6 × 10−7
cm2/s and as 1.05 × 10−6 cm2/s for the FeSSIF micelles.
Considering that the mucus layer only slightly affects the
diffusion coefficient at high taurocholate concentrations in the
fed state, while in the fasted state the diffusion is slowed down
by a factor of around three.10,60,61 VGI,fed/VGI,fasted was
considered to be equal to 1 during the calculations.
= − −D Mlog 4.14 0.417logUWL W (8)
2.2.4. Estimation of Fraction Absorbed Ratio Based on
Flux Results. The fraction absorbed (Fa) ratio for the











where Jfed and Jfasted are the measured flux with FeSSIF and
FaSSIF being in the donor compartment, respectively.
THe Fa ratio for the prediction of bioequivalence was







where test and reference are related to the flux measured for
the test and reference drug product correspondingly.
2.2.5. Calculation of Fraction Absorbed Ratios Based on
in Vivo Data. The Fa ratio for the prediction of food effect was






where AUCfed and AUCfasted are the area under the plasma
concentration−time curve (24 h) in fed and fasted states.
The fraction of the reference dose absorbed ratio (Fa,ref) for






where AUCtest and AUCreference are the area under the plasma
concentration−time curve (24 h) for the test and reference
products. When the 90% confidence interval of the ratio is
between 0.80 and 1.25, the two products are expected to be
bioequivalent.
Please note that the Fa ratio in itself contains dose
considerations as well (eq 13). This means that, in the case
of the formulations with different doses like SUBA-ITRA (test,
50 mg) and the Sporanox capsule (reference, 100 mg), aFa










Since the criteria for bioequivalence is determined in AUC
ratios (and Cmax ratios), regardless of the dose, Fa,ref (eq 12)
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2.2.6. Statistical Analyses. Concentrations were expressed
as means ± SD and were compared using a two-sample
Student’s t test. Differences were considered statistically
significant when p < 0.05.
3. RESULTS
First, the results of the different solubility measurements of
pure ITRA in several aqueous media, with and without bile
salts and formulation additives, are presented. Then the flux
experiments of the marketed formulations of ITRA (Sporanox
solution, Sporanox capsule, and SUBA-ITRA capsule) are
described.
3.1. Thermodynamic Solubility Assays. Thermodynam-
ic solubility measurements were carried out in several media
(Table 2). The solubility result obtained in SGF was found to
be in good agreement with the literature data, suggesting
around 4 μg/mL solubility in 0.1 M HCl solution.62,63 The
solubility value measured in pH 7.4 ASB containing surfactants
showed that sink conditions were ensured in the acceptor
compartment during the flux measurement. In the case of pH 5
and 6.5 media the solubility of the API was so low that it was
under the detection limit of the spectrophotometer. Therefore,
in these cases, kinetic solubility measurements, which were
expected to result in several times higher solubility values than
the equilibrium thermodynamic solubility,28 were chosen to
determine the solubilizing effect of bile micelles and
formulation additives on ITRA.
3.2. Kinetic Solubility Measurements. Kinetic solubility
measurements were carried out in the same media as the donor
media of the flux experiments (FaSSIF and FeSSIF) and also
their respective blank media. Additional assays were done in
FaSSIF and FeSSIF media in the presence of formulation
additives used in marketed formulations of ITRA to evaluate
the effect of these excipients on solubility. From the kinetic
solubility results shown in Figure 3, it could be concluded that
the FaSSIF and FeSSIF media were able to solubilize the API
to the same level. It seemed that the addition of HPMC or
HPMC-P only slightly changed the solubility of ITRA in
FeSSIF and also in FaSSIF media. On the other hand, HP-β-
CD addition significantly increased the solubility of ITRA in
both biorelevant media (in FaSSIF p < 0.001, in FeSSIF p <
0.001). The increase was more prominent in FaSSIF than in
FeSSIF, creating a significant difference between the solubility
values obtained from the different buffers in the presence of
cyclodextrin (p < 0.001).
In the blank media, even the kinetic solubility of the drug
was found to be under the detection limit of the
spectrophotometer (40 ng/mL).
3.3. Flux Experiments. For simulating the pH change
when the formulation goes from the stomach to the small
intestine in a fasted state, a media change was carried out from
SGF to FaSSIF. For the initial 30 min, the donor compartment
was filled with SGF and the acceptor compartment was not yet
connected to the donor. The dissolution of ITRA from the
different formulations in the donor compartment for that
period of time can be seen in Figure 4.a. ITRA added from
Sporanox solution stayed fully dissolved in SGF (476 μg/mL),
no precipitation was observed. Sporanox capsule started
releasing the API in SGF, but after reaching the maximum
level of supersaturation, it started precipitating as well. The
SUBA-ITRA capsule was only releasing a small amount of
ITRA since HPMC-P, the matrix polymer of the ASD is not
soluble in acidic media.
After 30 min, the media in the dissolution vessel was
converted to fasted state simulated intestinal fluid and the
acceptor compartment was added to the device. Changing the
pH triggered immediate precipitation in the donor compart-
ment for the Sporanox solution and further precipitation for
the Sporanox capsule. The SUBA-ITRA capsule only
disintegrated after the media change was conducted. In all
three cases, the donor media became very turbid, disabling the
in situ UV detection. For this reason, only the acceptor
concentrations are presented in Figure 4b after media change.
Early fluxes were calculated from the linear portion of the
appearance profiles (50−120 min) (Figure 5). Although the
dissolution and precipitation kinetics of the two capsules were
quite different, the flux results obtained showed no significant
difference (Figure 4b and Figure 5). The early flux of ITRA
from Sporanox solution was found to be ca. 4 times higher in
FaSSIF than any of the capsule forms (Figure 5).
For simulating the conditions after food intake in the
gastrointestinal tract, FeSSIF media was used in the donor
compartment. (No media change was carried out, and the
acceptor compartment was assembled into the dissolution
vessel from the beginning of the experiments, meaning the flux
experiment started from time zero.) For all of the formulations,
the donor media became very turbid right after the beginning
of the experiment, disabling the in situ UV detection. For this
reason, only the acceptor concentrations are presented in
Figure 6. In the case of the capsules, similar early flux results
were obtained, though the appearance profile of ITRA from
the Sporanox capsule showed a decrease in flux after 2 h, while
no change in flux was observed for the SUBA-ITRA capsule.
These profiles suggest that ITRA dissolving from the SUBA-
ITRA capsule is in a quite stable solution with a constant
concentration of the drug present in the donor compartment,
Table 2. Thermodynamic Solubility of ITRA in Different
Aqueous Media Determined by the Saturation Shake Flask
(SSF) Method
media SSF method (μg/mL)
pH 1.2 SGF 5.4 ± 0.44a
pH 5.0 FeSSIF blank <0.04b
pH 6.5 FaSSIF blank <0.04b,c
pH 7.4 ASB buffer 114.5 ± 0.58a
an = 3. bUnder the detection limit of the spectrophotometer.
cIntrinsic solubility.
Figure 3. Kinetic solubility values determined in FaSSIF and FeSSIF
media with or without additives.
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while ITRA dissolves and slowly precipitates from the
Sporanox capsule in FeSSIF solution.
The early flux result of the API from its cyclodextrin-based
solution was found to be superior to the capsule formulations
in the fed state (Figure 5). The appearance profile of the
Sporanox solution (decreasing flux) suggests precipitation in
the donor media. The absolute value of the measured flux from
the Sporanox capsule in the fed state (0.424 μg/min cm2) was
found to be in good agreement with previously reported in
vitro flux experiments carried out in smaller scale dissolution−
permeation setups.15,41
4. DISCUSSION
Fa ratios were calculated based on the results of the in vitro
kinetic solubility assays, as well as the flux assays. These ratio
values were examined on their ability to predict (1) the food
effect on different ITRA formulations and (2) the
bioequivalence test outcome comparing these formulations.
All predictions were compared to in vivo results published by
the European Medicines Agency (EMA) or the Food and Drug
Administration (FDA).
4.1. Prediction of Food Effect Based on in Vitro
Kinetic Solubility and Flux Assays. In the case of the
Sporanox solution, the predicted Fa ratios showed a slightly
negative (the ratio is less than 1) food effect, which is in good
agreement with the in vivo data (Figure 7) and also the
recommendation to take the solution before meals.48 Sporanox
capsules are advised to be taken after a meal, which seems
reasonable considering the in vivo results.47 It can be seen from
Figure 7 that both in vitro-based Fa calculations predict the in
vivo behavior well (positive food effect, Fa ratio more than 1).
It is interesting to see that, while positive food effect can be
Figure 4. Dissolution in SGF (left) and appearance profile (right) of ITRA from Sporanox solution (100 mg), the Sporanox capsule (100 mg), and
the SUBA-ITRA capsule (50 mg).
Figure 5. Early flux results of ITRA from Sporanox solution (100
mg), the Sporanox capsule (100 mg), and the SUBA-ITRA capsule
(50 mg) (donor media: FaSSIF or FeSSIF).
Figure 6. Appearance profile of ITRA from Sporanox solution (100
mg), the Sporanox capsule (100 mg), and the SUBA-ITRA capsule
(50 mg) in FeSSIF media.
Figure 7. Comparison of the predicted fraction absorbed ratios (fed/
fasted) for the estimation of food effect in the case of Sporanox
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easily seen from the flux results themselves (Figure 5), it is not
so straightforward in the case of the kinetic solubility results
(Figure 3). Since the kinetic solubility values do not differ
significantly between fasted or fed states, the positive food
effect can be explained by the fact that FeSSIF micelles are
smaller than FaSSIF ones, and therefore diffuse around three
times faster.10,60 The difference in size and the diffusion
coefficient explains why the results of the solubility-based
prediction also indicate a significant positive food effect for the
Sporanox capsule. In the case of the SUBA-ITRA capsule the
manufacturer claimed to have found a reduced food effect as
compared to the Sporanox capsule, and according to
information in the patient leaflet, the drug can be taken
regardless of meals.51 Although the flux-based Fa ratio seems to
show a slightly smaller food effect than the Sporanox capsule,
according to in vitro-based predictions, a positive food effect
can be anticipated.
4.2. Prediction of Bioequivalence Based on in Vitro
Flux and Kinetic Solubility Assays. The SUBA-ITRA
capsule containing half the ITRA dose of the brand capsule
was found in vivo to be therapeutically equivalent but not
bioequivalent to the Sporanox capsule, because of the
significant difference obtained between the area under the
concentration−time curve (AUC) values in the fasted state.51
The Fa,ref ratio in the fasted state was calculated as a ratio of the
AUC9 of the test and reference product (eq 12) and was found
to be 0.68 (Figure 8). Interestingly, the values of the maximum
concentration of the concentration−time curve (Cmax), and the
time when the Cmax is reached (tmax), of each of the two
formulations were found to be almost identical (Cmax ratio =
0.99, tmax ratio = 1).
51 Based on both in vitro predictions, Fa,ref
ratios around 1 were anticipated. From this comparison, it can
be seen that both in vitro Ffa,ref ratios are more in agreement
with Cmax ratios than AUC ratios. This seems to be rather
logical since the flux values used in the calculations refer to the
rate of absorption which can be expressed in vivo as Cmax/tmax.
Since tmax values were determined to be equal for both cases,
Cmax ratio can represent the in vivo initial rate of absorption. In
many cases, not much difference can be seen in the AUC ratio
and the Cmax ratio during bioequivalence studies because very
similar products with the same dose and identical or slightly
different excipients are compared. While the composition of
SUBA-ITRA ASD (HPMC-P instead of HPMC) might enable
the rate of absorption to be very similar to the reference
product, the halved dose and short gastric retention time in the
fasted state might be responsible for the significantly reduced
AUC value. These effects cannot be modeled by the in vitro
methods used in this study.
In the case of fed state studies in vivo, the Fa,ref ratio (SUBA-
ITRA/Sporanox) is ca. 1 (0.88) (Figure 8), and the Cmax values
are also almost equivalent (ratio = 0.93),51 suggesting a similar
initial absorption rate. Both the kinetic solubility and flux-
based predictions showed excellent agreement with the fed
state in vivo results (Figure 8).
Sporanox solution and the Sporanox capsule were not
compared in the fasted state in clinical studies published by the
FDA, so the in vivo data shown in Figure 9 was taken from a
publication by Brouwers et al.64 In Figure 9, it can be seen that
the flux-based Fa,ref ratio gives a fair estimate to the in vivo
results, while kinetic solubility overestimates the positive effect
of the cyclodextrin.
Sporanox solution was marketed 5 years after the capsule by
Janssen Pharmaceutica. When launching the new formulation,
it was compared to the capsule form.47 Since it was already
known that the solution was recommended to be taken before
meals and that the solid formulation should be taken after a
meal, Sporanox solution in the fasted state was compared to
the Sporanox capsule in the fed state. (Figure 9) Both in vitro
Fa,ref predictions showed superior bioavailability of ITRA from
solution, which agreed well with the in vivo results. The in vivo
Fa,ref ratio of ITRA from Sporanox solution was found to be ca.
2.5 times higher than from the capsule forms. Since the
bioavailability of ITRA was greater from Sporanox solution, the
solution and the capsule were therefore not bioequivalent
products according to FDA.47
Comparing the two in vitro-based Fa,ref prediction
approaches, it has to be noted that flux-based predictions
were closer to the in vivo results when the HP-β-CD containing
solution and the HPMC containing a solid formulation were
compared. This might be because in vitro kinetic solubility-
based prediction requires that the diffusion coefficients of not
just the bile micelles but also the cyclodextrin complexes are
estimated. This estimate is highly dependent on the
assumption of the HP-β-CD−ITRA ratio (in this case, it was
assumed to be 3:1).57 Moreover, this model does not consider
aggregation of CD complexes or any interplay between CD
and bile micelles, although this may be possible according to
the literature.65 It must also be noted that the solubility-based
Figure 8. Predicted fraction absorbed ratios for the comparison of
SUBA-ITRA (test) and Sporanox (reference) capsules in fasted and
fed conditions and in vivo data from the bioequivalence study results.
Figure 9. Predicted fraction absorbed ratios for the comparison
Sporanox solution and Sporanox capsule in fasted and fed conditions
and in vivo data.
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approach requires the investigation of solubility data in each
media, both with and without the formulation additives, which
is a more labor-intensive task than performing flux measure-
ments.
It has to be noted that although no exact dissolution data
was obtained due to the limitations of the fiber optic technique
in extremely turbid media, it is possible to use manual sampling
and offline analysis if needed in concert with the BioFLUX
setup.
5. CONCLUSIONS
This study demonstrated that kinetic solubility and flux values
measured under biorelevant conditions could be used as input
parameters for biopharmaceutics modeling and simulations to
estimate food effect and bioequivalence.
Both the kinetic solubility and the flux-based prediction
methods were highly capable of determining the slightly
negative food effect in the case of Sporanox solution, and a
pronounced positive food effect for the Sporanox capsule. The
flux-based method was able to predict even a positive, but
slightly reduced food effect for the SUBA-ITRA capsule.
Superior bioavailability was predicted when comparing
Sporanox solution to the Sporanox capsule, which was found
to be in good agreement with in vivo data published by the
FDA. The limitations of in vitro methods were met when
comparing the 50 mg SUBA-ITRA capsule to the 100 mg
Sporanox capsule. Namely, the in vitro methods provided
accurate information about the rate of absorption but were not
able to predict the reduced AUC values caused by the halved
dose and shorter gastric retention in the fasted state.
Comparing the in vitro flux and solubility-based Fa
prediction methods, it was observed that, in the case of
complex media containing bile micelles and cyclodextrins, it is
advantageous to use the flux-based prediction. This model only
uses the measured flux values, while solubility-based prediction
requires accurate assumptions about the fraction of drug
solubilized by micelles, complexation, and also the diffusivity of
these species through the UWL.
It could also be concluded that the flux approach is less labor
intensive, providing good IVIVC when compared to the
solubility-based approach, especially in the case of complex
formulations and biorelevant media.
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Measurement of Ionizable Drugs - Consensus Recommendations for
Improving Data Quality. ADMET DMPK 2016, 4 (2), 117−178.
(55) Bendels, S.; Tsinman, O.; Wagner, B. R.; Lipp, D.; Parrilla, I.;
Kansy, M.; Avdeef, A. PAMPA-Excipient Classification Gradient Map.
Pharm. Res. 2006, 23 (11), 2525−2535.
(56) FDA. https://www.accessdata.fda.gov/scripts/cder/
dissolution/dsp_getallData.cfm (accessed 20/06/2019).
(57) Peeters, J.; Neeskens, P.; Tollenaere, J. P.; Van Remoortere, P.;
Brewster, M. E. Characterization of the Interaction of 2-
hydroxypropyl-β-cyclodextrin with Itraconazole at PH 2, 4, and 7. J.
Pharm. Sci. 2002, 91 (6), 1414−1422.
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